# Correlation of Liver Stiffness Measurements with AST to Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) Scores in Pediatric Patients with Hepatitis B or Liver Transplantation Bhumi Patel<sup>1</sup>, Jean Molleston<sup>2</sup>

<sup>1</sup>Indiana University School of Medicine; <sup>2</sup>Indiana University School of Medicine, Department of Pediatric Gastroenterology, Hepatology and Nutrition

## Background and Objective:

Current standard for assessing liver fibrosis is biopsy. However, its invasive nature, cost, and limited sampling are problematic for many patients. Fibroscan is a technology that utilizes transient elastography (TE) to measure liver stiffness (LSM) quickly and non-invasively. TE is a novel method in children and has shown to be a measure of fibrosis. Biomarkers for hepatic fibrosis include the APRI and FIB-4 scores, which are not well-studied in children. Our goal is to correlate APRI and FIB-4 with LSM in children who have hepatitis B (hep B) or have received liver transplants (LT).

### Methods:

LSM scores of 26 children with hep B and 41 children with LT were retrieved from a research database at Riley Hospital for Children. We then obtained laboratory results closest to the date (+/- 1 year) of their TE. Those results were used to determine APRI and FIB-4 scores. Spearman correlation ( $r_s$ ) was determined between LSM/APRI, LSM/FIB-4, and APRI/FIB-4 in each disease.

### **Results:**

Table 1. Spearman Correlations for LSM/APRI, LSM/FIB-4, and APRI/FIB-4 in Hep B and LT

Disease	Comparison		Spearman Correlation $(r_s)$
Hep B	LSM	APRI	0.321
	LSM	FIB-4	0.376
	APRI	FIB-4	0.731*
LT	LSM	APRI	0.303
	LSM	FIB-4	0.526*
	APRI	FIB-4	0.632*

\*p < 0.05

### **Conclusion and Potential Impact:**

The moderate correlation of LSM with FIB-4 in LT shows potential for future clinical use, but the correlations of LSM with APRI in both conditions and the correlation of LSM with FIB-4 in Hep B are weaker. APRI and FIB-4 are strongly correlated in these children. However, additional studies with larger sample sizes should be completed. Because patients with LT and chronic hep B regularly need longitudinal evaluation, finding non-invasive tools are important to ensure compliance and ease.